CROI 2015 Program and Abstracts

Oral Sessions

92 Majority of XDR TB Cases Are Due to Transmission in a High-HIV- Prevalence Setting N. Sarita Shah 1 ; James C. Brust 2 ; Barun Mathema 3 ;Thuli Mthiyane 4 ; Nazir Ismail 5 ; Pravi Moodley 6 ; Koleka Mlisana 8 ; Salim Allana 7 ; Jonathan Smith 7 ; Neel R. Gandhi 7 1 US Centers for Disease Control and Prevention, Atlanta, GA, US; 2 Montefiore Medical Center & Albert Einstein College of Medicine, Bronx, NY, US; 3 Columbia University Mailman School of Public Health, New York, NY, US; 4 University of KwaZulu-Natal, Durban, South Africa; 5 National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa; 6 University of KwaZulu-Natal & National Health Laboratory System, Durban, South Africa; 7 Emory University Rollins School of Public Health, Atlanta, GA, US; 8 University of KwaZulu-Natal & National Health Laboratory Service, Durban, South Africa 93 Linkage to HIV/TB Care in South Africa: A Randomized Trial of Health Navigators Ingrid V. Bassett 2 ; Sharon M. Coleman 1 ; Janet Giddy 4 ; Laura M. Bogart 3 ; Christine E. Chaisson 1 ; Douglas Ross 5 ;Tessa Govender 4 ; Kenneth A. Freedberg 2 ; Rochelle P.Walensky 2 ; Elena Losina 2 1 Boston University School of Public Health, Boston, MA, US; 2 Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 3 Boston Children’s Hospital, Harvard Medical School, Boston, MA, US; 4 McCord Hospital, Durban, South Africa; 5 St. Mary’s Hospital, Mariannhill, South Africa Paula Munderi 1 ; Jonathan B. Levin 1 ; Zacchaeus Anywaine 1 ; Ronnie Kasirye 1 ; Anatoli Kamali 1 ; Andrew J. Nunn 2 ; Heiner Grosskurth 3 On behalf of COSTOP ResearchTeam 1 MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda; 2 University College London, London, United Kingdom; 3 London School of Hygiene and Tropical Medicine, London, United Kingdom 95LB High-Dose Rifampin, SQ109 and Moxifloxacin for Treating TB: The PanACEA MAMS-TB Trial 10:00 am– 12:15 pm Factors Affecting HIV Care and Outcome: Global Perspective Moderators Ruanne V. Barnabas , University of Washington, Seattle, WA, US Elizabeth Bukusi , University of California San Francisco, San Francisco, CA, US 96 Special Presentation: PEPFAR 3.0: Controlling the Epidemic and Delivering on the Promise of an AIDS-Free Generation Ambassador Deborah L. Birx, MD US Department of State, Washington, DC, US 97 Joint Estimation of HIV Progression and Survival: A Pooled Analysis of 25 Countries Tara D. Mangal On behalf of the UNAIDSWorking Group on CD4 Progression and Mortality Among HIV Seroconverters including the CASCADE Collaboration in EuroCoord Imperial College London, London, United Kingdom 98 Impact of Emergency Department HIV Testing and Linkage to Care: 25 Years’Experience Gabor Kelen 3 ; Eshan U. Patel 2 ;Yu-Hsiang Hsieh 3 ; Oliver B. Laeyendecker 2 ; Judy Shahan 3 ; William Clarke 3 ; Jordyn L. Manucci 3 ; Richard Rothman 3 ; Thomas C. Quinn 2 1 Johns Hopkins University School of Medicine, Baltimore, MD, US; 2 National Institute of Allergy and Infectious Diseases (NIAID), Baltimore, MD, US; 3 Johns Hopkins University School of Medicine, Baltimore, MD, US 99 Linkage to Care and Viral Suppression Among New HIV Diagnoses, New York City, 2006-13 EllenW.Wiewel; Lucia V. Torian ; Qiang Xia; Sarah L. Braunstein New York City Department of Health and Mental Hygiene, Long Island City, NY, US 94 Is It Safe to Stop Cotrimoxazole in Adults on ART: COSTOP, a Noninferiority RCT Martin J. Boeree 1 ; Michael Hoelscher 2 On behalf of the PanACEA consortium 1 Radboudumc, Nijmegen, Netherlands; 2 University of Munich, Munich, Germany Session O-8 Special Presentation and Oral Abstracts

100 Care and Viral Suppression AmongWomen, 18 US Jurisdictions Ndidi Ike ; Angela L. Hernandez; Qian An;Taoying Huang; H. Irene Hall US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US 101 Time Above 1500 Copies/ml: A Viral-Load Measure for Assessing Transmission Risk of HIV-Positive Patients in Care 1 Centers for Disease Control and Prevention, Atlanta, GA, US; 2 Boston University School of Medicine, Boston, MA, US; 3 Colleges of Medicine and Nursing, SUNY Downstate Medical Center, Brooklyn, NY, US; 4 Johns Hopkins University School of Medicine, Baltimore, MD, US; 5 University of Alabama at Birmingham, Birmingham, AL, US; 6 Miller School of Medicine, University of Miami, Miami, FL, US; 7 Baylor College of Medicine, Houston, TX, US 102 Incidence and Risk Factors for Sexual Assault Among MSM and Young Women in Coastal Kenya Adrian D. Smith 1 ; Sam Rogers 1 ; ElizabethWahome 2 ; Marianne Darwinkel 2 ; Susan M. Graham 3 ; Eduard J. Sanders 2 1 Nuffield Department of Population Health, Oxford, United Kingdom; 2 Centre for Geographic Medicine Research – Coast, Kilifi, Kenya; 3 University of Washington, Seattle, WA, US 103LB Impact of the Ebola Epidemic on HIV Care in Macenta, Forest Guinea, 2014 David Leuenberger 1 ; Jean Hébélamou 1 ; Stefan Strahm 1 ; GillesWandeler 2 ; Nathalie de Rekeneire 3 ; François Dabis 3 On behalf of International Epidemiological Databases to Evaluate AIDS -West Africa 1 Mission Philafricaine, Conakry, Guinea; 2 Department of Infectious Diseases, University Hospital Bern, Bern, Switzerland; 3 Université Bordeaux, ISPED, Centre Inserm U897-Epidemiologie- Biostatistique, Bordeaux, France 103-ALB Favipiravir in Patients with Ebola Virus Disease: Early Results of the JIKI trial in Guinea Daouda Sissoko 1 , Elin Folkesson 2 , M’lebing Abdoul 3 , Abdoul Habib Beavogui 4 , Stephan Gunther 6 , Susan Shepherd 3 , Christine Danel 1 ,France Mentre 5 , Xavier Anglaret 1 , Denis Malvy 1 1 Inserm U897, Université de Bordeaux, Bordeaux, France; 2 Médecins Sans Frontières, Bruxelles, Belgium; 3 ALIMA, Montreuil, France; 4 Centre de Formation et de Recherche en Santé Rurale de Maférinyah, Conakry, Guinée; 5 Inserm U738, Université Paris Diderot, Paris, France; 6 Bernhard- Nocht-Institut für Tropenmedizin, Hamburg, Germany Rebound Moderators Francoise Barre-Sinoussi , Institut Pasteur Celsa A. Spina , University of California San Diego, La Jolla, CA, US 104LB Durable Control of Viral Rebound in Humanized Mice by ABX464 Targeting Rev Functions Noelie Campos 1 ; Renier Myburgh 3 ; Aude Garcel 1 ; AudreyVautrin 2 ; Laure Lapasset 2 ; Katjana Tantale 2 ; MarkWainberg 4 ; Roberto Speck 3 ; Didier Scherrer 1 ; Jamal Tazi 2 1 ABIVAX, Montpellier, France; 2 University of Montpellier, Montpellier, France; 3 University of Zurich, Zurich, Switzerland; 4 McGill AIDS Center, Montréal, Canada 105 Residual Viremia Caused by Clonally Expanded Tumor-Infiltrating CD4+ Cells Francesco R. Simonetti 1 ; Michele D. Sobolowski 2 ; Shawn Hill 1 ;Wei Shao 3 ; Elizabeth Fyne 2 ; XiaolinWu 1 ; John M. Coffin 4 ; Stephen H. Hughes 1 ; JohnW. Mellors 2 ; Frank Maldarelli 1 1 National Cancer Institute (NCI), Frederick, MD, US; 2 University of Pittsburgh, Pittsburg, PA, US; 3 Frederick National Laboratory for Cancer Research, Frederick, MD, US; 4 Tufts University, Boston, MA, US; 5 National Cancer Institute (NCI), Frederick, MD, US 106 Analysis of HIV RNA in Single Cells Reveals Clonal Expansions and Defective Genomes AnnWiegand 1 ; Jonathan Spindler 1 ;Wei Shao 2 ; Feiyu Hong 3 ; Anthony R. Cillo 3 ; Elias Halvas 3 ; Elizabeth Fyne 3 ; John M. Coffin 4 ; JohnW. Mellors 3 ; Mary F. Kearney 1 1 National Cancer Institute, Frederick, MD, MD, US; 2 Leidos, Frederick, MD, US; 3 University of Pittsburgh, Pittsburgh, PA, US; 4 Tufts University, Boston, MA, US Lytt I. Gardner 1 ; Gary Marks 1 ; Charles Rose 1 ; Meg Sullivan 2 ; Susan Holman 3 ; Jeanne Keruly 4 ; Anne Zinski 5 ; Allan Rodriguez 6 ;Thomas Giordano 7 Session O-9 Oral Abstracts Room 6D 10:00 am– 12:15 pm New Insights Into HIV Persistence, Latency Reversal, and Viremia

Wednesday, February 25, 2015 • Oral Sessions

Room 6E

11

CROI 2015